Search

Your search keyword '"Ozaki, Toshifumi"' showing total 19 results
Start Over Author "Ozaki, Toshifumi" Journal japanese journal of clinical oncology
19 results on '"Ozaki, Toshifumi"'

9. randomized phase III trial of denosumab before curettage for giant cell tumor of bone. JCOG1610.

Author

Urakawa, Hiroshi, Nagano, Akihito, Machida, Ryunosuke, Tanaka, Kazuhiro, Kataoka, Tomoko, Sekino, Yuta, Nishida, Yoshihiro, Takahashi, Mitsuru, Kunisada, Toshiyuki, Kawano, Masanori, Yoshida, Yukihiro, Takagi, Tatsuya, Sato, Kenji, Hiruma, Toru, Hatano, Hiroshi, Tsukushi, Satoshi, Sakamoto, Akio, Akisue, Toshihiro, Hiraoka, Koji, and Ozaki, Toshifumi

Published
2022
Full Text
View/download PDF

10. Immunotherapy for sarcomas

Author

Nakata, Eiji, primary, Fujiwara, Tomohiro, additional, Kunisada, Toshiyuki, additional, Ito, Tastuo, additional, Takihira, Shota, additional, and Ozaki, Toshifumi, additional

Published
2021
Full Text
View/download PDF

13. A randomized phase III trial of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group Study JCOG1610

Author

Urakawa, Hiroshi, primary, Mizusawa, Junki, additional, Tanaka, Kazuhiro, additional, Eba, Junko, additional, Hiraga, Hiroaki, additional, Kawai, Akira, additional, Nishida, Yoshihiro, additional, Hosaka, Masami, additional, Iwamoto, Yukihide, additional, Fukuda, Haruhiko, additional, and Ozaki, Toshifumi, additional

Published
2019
Full Text
View/download PDF

18. A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup

Author

Kawai, Akira, primary, Araki, Nobuhito, additional, Hiraga, Hiroaki, additional, Sugiura, Hideshi, additional, Matsumine, Akihiko, additional, Ozaki, Toshifumi, additional, Ueda, Takafumi, additional, Ishii, Takeshi, additional, Esaki, Taito, additional, Machida, Michiko, additional, and Fukasawa, Nobuaki, additional

Published
2016
Full Text
View/download PDF

19. A randomized phase III trial of denosumab before curettage for giant cell tumor of bone. JCOG1610.

Author

Urakawa H, Nagano A, Machida R, Tanaka K, Kataoka T, Sekino Y, Nishida Y, Takahashi M, Kunisada T, Kawano M, Yoshida Y, Takagi T, Sato K, Hiruma T, Hatano H, Tsukushi S, Sakamoto A, Akisue T, Hiraoka K, and Ozaki T

Subjects
Bone Density Conservation Agents therapeutic use, Curettage, Humans, Bone Neoplasms drug therapy, Bone Neoplasms surgery, Denosumab therapeutic use, Giant Cell Tumor of Bone drug therapy, Giant Cell Tumor of Bone surgery
Abstract

Objectives: The aim of JCOG1610 (randomized controlled phase III trial) was to confirm the superiority of preoperative denosumab to curettage with adjuvant local therapy for patients with giant cell tumor of bone without possible post-operative large bone defect., Methods: The primary endpoint was relapse-free survival and the total sample size was set at 106 patients. Patient accrual began in October 2017. However, the accrual was terminated in December 2020 due to a recommendation from the Data and Safety Monitoring Committee because of poor patient accrual. Now, we report the descriptive results obtained in this study., Results: A total of 18 patients had been registered from 13 Japanese institutions at the time of termination on December 2020. Eleven patients were assigned to Arm A (curettage and adjuvant local therapy) and 7 to Arm B (preoperative denosumab, curettage and adjuvant local therapy). Median follow-up period was 1.6 (range: 0.5-2.8) years. Protocol treatment was completed in all but one patient in Arm A who had a pathological fracture before surgery. All patients in Arm B were treated with five courses of preoperative denosumab. Relapse-free survival proportions in Arm A and B were 90.0% (95% confidence interval: 47.3-98.5) and 100% (100-100) at 1 year, and 60.0% (19.0-85.5) and 62.5% (14.2-89.3) at 2 years, respectively [hazard ratio (95% confidence interval): 1.51 (0.24-9.41)]., Conclusion: In terms of relapse-free survival, the superiority of preoperative denosumab was not observed in patients with giant cell tumor of bone without possible post-operative large bone defect., (© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results